

From: s 22
To: s 22 [SCHOFIELD, Lisa](#)
Subject: FW: Pfizer/BioNTech COVID-19 Vaccine - positive early data released last night. [SEC=OFFICIAL]
Date: Thursday, 2 July 2020 6:13:31 PM
Attachments: [image001.png](#)
[Pfizer US Preliminary Clinical Release 7-1-20 FINAL.pdf](#)

FYI

From: s 47F
Sent: Thursday, 2 July 2020 10:05 AM
To: s 22
Subject: Pfizer/BioNTech COVID-19 Vaccine - positive early data released last night. [SEC=No Protective Marking]
Hi s 22

Just flagging the attached, which was released overnight by Pfizer & BioNTech. Some positive early data from an ongoing Phase 1/2 study.

Key points:

“These preliminary data, together with additional preclinical and clinical data being generated, will be used by the two companies to determine a dose level and select among multiple vaccine candidates to seek to progress to a large, global Phase 2b/3 safety and efficacy trial. That trial may involve up to 30,000 healthy participants and is anticipated to begin in late July 2020, if regulatory approval to proceed is received. The preliminary clinical data from this ongoing study have been submitted for potential publication in a peer-reviewed journal and is available on an [online preprint manuscript server](#).”

“Efforts to manufacture the leading candidates, at risk, are gearing up. In case the safety and efficacy study is successful, and the vaccine receives regulatory approval, the companies are expecting to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.”

My Global colleagues are enthusiastic to discuss this further, and possible opportunities in Australia, at a senior level at the earliest opportunity.

Please feel free to call any time.

Thanks

s 47F

www.pfizer.com.au

Level 3, 500 Collins Street
Melbourne, VIC, 3000

s 47F



LEGAL NOTICE Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee(s) only. Access to this e-mail by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you are not an addressee, please inform the sender immediately. Pfizer Australia has its registered office at Level 15-18, 151 Clarence Street,

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982 (CTH)
BY THE DEPARTMENT OF HEALTH